Brief: Antengene says Collaboration Agreement Between Antengene And Hansoh Pharma
11/08/2023 02:23
Aug 11 (Reuters) - Antengene Corporation Ltd 6996.HK :
* COLLABORATION AGREEMENT BETWEEN ANTENGENE AND HANSOH
PHARMA
* ANTENGENE WILL RECEIVE UP TO RMB200 MILLION OF UPFRONT
PAYMENTS
FROM HANSOH PHARMA
* ANTENGENE WILL CONTINUE TO BE RESPONSIBLE FOR RESEARCH AND
DEVELOPMENT, AMONG OTHERS AND DISTRIBUTION OF XPOVIO®
* HANSOH PHARMA WILL BE EXCLUSIVELY RESPONSIBLE FOR
COMMERCIALIZATION OF XPOVIO® IN MAINLAND OF CHINA
Further company coverage: 6996.HK
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106